Kaul Deepak, Gautam A, Varma S, Ahlawat A
Department of Experimental Medicine & Biotechnology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Mol Cell Biochem. 2008 Jul;314(1-2):19-23. doi: 10.1007/s11010-008-9760-2. Epub 2008 Apr 13.
Keeping in view the fact that a single acquired genetic abnormality "Bcr-Abl chimeric gene" accompanied by elevated telomerase activity has been widely recognized to be responsible for the leukemic myelopoiesis observed in chronic myeloid leukemia (CML), the present study was addressed to understand as to how selective and specific knock-down of human telomerase reverse transcriptase (hTERT) gene within mononuclear cells derived from untreated CML subjects could influence the apoptotic, genotypic (such as Bcr-Abl; C-myc; Bcl-2; IL-6; GMCSF; IL-3; and acetylated H(3) and H(4)), and phenotypic (such as CD34 and CD89) characteristics of these cells. Based upon these results, we propose that hTERT gene-based drug design may be useful in the treatment of leukemic myelopoiesis.
鉴于单个获得性基因异常“Bcr-Abl嵌合基因”伴随端粒酶活性升高已被广泛认为是慢性粒细胞白血病（CML）中观察到的白血病髓系造血的原因，本研究旨在了解选择性和特异性敲低未经治疗的CML患者单核细胞中的人端粒酶逆转录酶（hTERT）基因如何影响这些细胞的凋亡、基因型（如Bcr-Abl、C-myc、Bcl-2、IL-6、GMCSF、IL-3以及乙酰化H(3)和H(4)）和表型（如CD34和CD89）特征。基于这些结果，我们提出基于hTERT基因的药物设计可能对白血病髓系造血的治疗有用。
